ribosomal protein L35aGenealiases: DBA5 · L35A · eL33
Q-omics provides the consensus-scored RPL35A profile across patient tissues and cancer cell-line models. RPL35A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL35A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPL35A protein abundance shows 23,265 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where RPL35A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35A survival associations across molecular data types. RPL35A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35A RNA expression–survival associations across cancer types. High RPL35A expression shows unfavorable associations in LIHC, ACC, PAAD, KICH and KIRP, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL35A RNA expression.
This table summarizes RPL35A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL35A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35A shows higher tumor expression in KIRC, LIHC, COAD, HNSC, KIRP and LUSC. The KIRC box plot shows higher RPL35A RNA expression in tumor versus normal tissue (log2 FC = +1.040, t-test p < 0.001).
This table shows molecular features associated with RPL35A in patient tissues and cancer cell lines. In patient samples, RPL35A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL35A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
